Biomea Fusion, Inc.
NASDAQ:BMEABiotechnology
-$0.03 today
- Market cap
- $53.18M
- Beta
- -0.33
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.62
Volume 3.50M
Average 1.52M
BMEA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Biomea Fusion, Inc.NASDAQ: BMEA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $46K fell 90.2% year over year, behind the -46.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.1% from the prior quarter. Over 3 fiscal years it compounded at +26.8% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -90.2% toward the trailing-twelve-month pace of -46.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.41M USD
- Year-over-year change
- -19.4%
- 4-year CAGR
- +54.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.41M | -19.4% |
| FY2024 | 2024-12-31 | 1.75M | +15.4% |
| FY2023 | 2023-12-31 | 1.52M | +119.2% |
| FY2022 | 2022-12-31 | 691K | +177.5% |
| FY2021 | 2021-12-31 | 249K | — |
Depreciation & Amortization vs competitors
How BMEA compares with its peers on the latest reported figures
- BMEA's LTM Mar 2026 depreciation & amortization of $960K is the 5th largest of the 9 companies compared; the peer median is $884K.
- Its year-over-year change of -46.5% is the 8th highest of 9, against a peer median of -2.8%.
- Over three fiscal years its annual growth of +26.8% compares with a peer median of +29.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.7M | -8.9% | +8.8% | 6.7% | |
CBUSCibus, Inc. | LTM Mar 2026 | $5.46M | -18.2% | +56.9% | 127.4% |
| LTM Mar 2026 | $1.74M | +3.4% | — | 44.2% | |
| LTM Mar 2026 | $1.12M | +22.5% | +35.7% | — | |
| LTM Mar 2026 | $960K | -46.5% | +26.8% | — | |
| LTM Mar 2026 | $648K | +132.3% | +52.6% | — | |
| LTM Mar 2026 | $645K | -25.8% | +27.3% | — | |
| LTM Mar 2026 | $158K | +4.6% | +29.7% | — | |
| LTM Mar 2026 | $131K | -84.0% | -41.1% | — | |
| Peer median (excluding BMEA) | $884K | -2.8% | +29.7% | 44.2% | |
Competitors are the stored peer set for BMEA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (41.57M) | (81.83M) | (117.26M) | (138.43M) | (61.8M) |
| Depreciation & Amortization | 249K | 691K | 1.52M | 1.75M | 1.41M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.23M | 10.34M | 14.13M | 19.09M | 9.52M |
| Change in Working Capital | (1.57M) | 7.67M | 2.33M | (5.15M) | (3.7M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 640K | 2.96M | 2.56M | 6.09M | (9.7M) |
| Other Working Capital | (2.21M) | 4.71M | (232K) | (11.24M) | 6M |
| Other Non-Cash Items | 1.22M | 715K | 2.69M | 2.84M | (15.81M) |
| Operating Cash Flow | (35.44M) | (62.42M) | (96.59M) | (119.89M) | (70.37M) |
| Capital Expenditures | (3.17M) | (1.03M) | (3.37M) | (362K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (38.49M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 8.31M | 28.37M | 1.15M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (33.35M) | 27.34M | (2.22M) | (362K) | 0 |
| Debt Repayment | (36K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 153.22M | 0 | 161.8M | 1.67M | 67.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.24M | 2M | 0 | 0 |
| Financing Cash Flow | 153.19M | 1.24M | 163.8M | 1.67M | 67.9M |
| Effect of Forex Changes | (351K) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 84.04M | (33.84M) | 64.99M | (118.59M) | (2.47M) |
| Free Cash Flow | (38.61M) | (63.45M) | (99.96M) | (120.26M) | (70.37M) |
Biomea Fusion, Inc.
NASDAQ:BMEA
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.